Nitisinone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nitisinone" in English language version.

refsWebsite

Global rank English rank

25nih.gov

4^th place

18doi.org

2^nd place

3web.archive.org

1^st place

3harvard.edu

18^th place

17^th place

2drugs.com

399^th place

333^rd place

2worldcat.org

5^th place

2semanticscholar.org

11^th place

8^th place

2fda.gov

447^th place

338^th place

1canada.ca

1,712^th place

1,063^rd place

1handle.net

102^nd place

76^th place

1springer.com

274^th place

309^th place

1dermnetnz.org

7,563^rd place

5,361^st place

1rarediseases.org

5,181^st place

3,260^th place

1sobi.com

low place

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

dermnetnz.org (Global: 7,563^rd place; English: 5,361^st place)

"Alkaptonuria and ochronosis". DermNet. 26 October 2023. Retrieved 22 May 2025.

doi.org (Global: 2^nd place; English: 2^nd place)

Das AM (2017). "Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)". The Application of Clinical Genetics. 10: 43–48. doi:10.2147/TACG.S113310. ISSN 1178-704X. PMC 5533484. PMID 28769581.
Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Bröijersén A, et al. (1 September 2020). "Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial". The Lancet. Diabetes & Endocrinology. 8 (9): 762–772. doi:10.1016/S2213-8587(20)30228-X. hdl:11365/1115671. PMID 32822600.
Lock EA (2017). "From Weed Killer to Wonder Drug". In Tanguay RM (ed.). Hereditary Tyrosinemia: Pathogenesis, Screening and Management. Advances in Experimental Medicine and Biology. Vol. 959. Cham: Springer International Publishing. pp. 175–185. doi:10.1007/978-3-319-55780-9_16. ISBN 978-3-319-55780-9. PMID 28755195. Retrieved 21 May 2025.
McKiernan PJ (2006). "Nitisinone in the treatment of hereditary tyrosinaemia type 1". Drugs. 66 (6): 743–750. doi:10.2165/00003495-200666060-00002. PMID 16706549. S2CID 24239547.
Perdomo HD, Guizzo MG, Barletta AB, Nunes RD, Dias FA, Sorgine MH, et al. (22 August 2016). "Tyrosine Detoxification Is an Essential Trait in the Life History of Blood-Feeding Arthropods". Current Biology. 26 (16): 2188–2193. Bibcode:2016CBio...26.2188S. doi:10.1016/j.cub.2016.06.025. PMID 27476595.
Haines LR, Casas-Sánchez A, Adung'a VO, Vionette-Amaral RJ, Quek S, Rose C, et al. (26 January 2021). "Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis". PLOS Biology. 19 (1) e3000796. doi:10.1371/journal.pbio.3000796. PMC 7837477. PMID 33497373.
Matias J, Tang X, Cibichakravarthy B, DePonte K, Wu MJ, Fikrig E, et al. (1 January 2024). "Metabolomic changes associated with acquired resistance to Ixodes scapularis". Ticks and Tick-borne Diseases. 15 (1) 102279. doi:10.1016/j.ttbdis.2023.102279. PMID 37972499.
Duke SO, Burgess ER, Swale DR, McComic SE (1 August 2023). "Defining the toxicological profile of 4-hydroxyphenylpyruvate dioxygenase-directed herbicides to Aedes aegypti and Amblyomma americanum". Pesticide Biochemistry and Physiology. 194 105532. Bibcode:2023PBioP.19405532M. doi:10.1016/j.pestbp.2023.105532. PMID 37532340.
Haines LR, Trett A, Rose C, García N, Sterkel M, McGuinness D, et al. (March 2025). "Anopheles mosquito survival and pharmacokinetic modeling show the mosquitocidal activity of nitisinone". Science Translational Medicine. 17 (791) eadr4827. doi:10.1126/scitranslmed.adr4827. PMID 40138457.
Sterkel M, Martins AJ, BP Lima J, L Oliveira P, Vergaray Ramirez MA (2022). "On the use of inhibitors of 4-hydroxyphenylpyruvate dioxygenase as a vector-selective insecticide in the control of mosquitoes". Pest Management Science. 78 (2): 692–702. doi:10.1002/ps.6679. PMID 34647418.
Stavrou-Dowd ZT, Parsons G, Rose C, Brown F, Lees RS, Acosta-Serrano Á, et al. (July 2025). "The β-triketone, nitisinone, kills insecticide-resistant mosquitoes through cuticular uptake". Parasites & Vectors. 18 (1) 316. doi:10.1186/s13071-025-06939-0. PMC 12315382. PMID 40745331.
Rodenburg IL, Harding CO, Hollak CE, Heiner-Fokkema MR, van Spronsen FJ, van Ginkel WG (December 2019). "Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1". Paediatric Drugs. 21 (6): 413–426. doi:10.1007/s40272-019-00364-4. ISSN 1179-2019. PMC 6885500. PMID 31667718.
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, et al. (August 1998). "From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug". Journal of Inherited Metabolic Disease. 21 (5): 498–506. doi:10.1023/A:1005458703363. PMID 9728330. S2CID 6717818.
Kavana M, Moran GR (September 2003). "Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione". Biochemistry. 42 (34): 10238–10245. doi:10.1021/bi034658b. PMID 12939152.
Mitchell G, Bartlett DW, Fraser TE, Hawkes TR, Holt DC, Townson JK, et al. (February 2001). "Mesotrione: a new selective herbicide for use in maize". Pest Management Science. 57 (2): 120–128. doi:10.1002/1526-4998(200102)57:2<120::AID-PS254>3.0.CO;2-E. PMID 11455642.
Moran GR (January 2005). "4-Hydroxyphenylpyruvate dioxygenase". Archives of Biochemistry and Biophysics. 433 (1): 117–128. doi:10.1016/j.abb.2004.08.015. PMID 15581571.
Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, et al. (July 1995). "Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione". Toxicology and Applied Pharmacology. 133 (1): 12–19. Bibcode:1995ToxAP.133...12E. doi:10.1006/taap.1995.1121. PMID 7597701.
Lindstedt S, Odelhög B (1987). "4-Hydroxyphenylpyruvate dioxygenase from human liver". In Kaufman S (ed.). Metabolism of Aromatic Amino Acids and Amines. Methods in Enzymology. Vol. 142. pp. 139–142. doi:10.1016/S0076-6879(87)42021-1. ISBN 978-0-12-182042-8. PMID 3037254.

drugs.com (Global: 399^th place; English: 333^rd place)

"Harliku (nitisinone) FDA Approval History". Drugs.com. 30 June 2025. Retrieved 5 July 2025.
"FDA Approves Harliku (nitisinone) for the Treatment of Patients with Alkaptonuria". Drugs.com (Press release). 19 June 2025. Retrieved 5 July 2025.

fda.gov (Global: 447^th place; English: 338^th place)

accessdata.fda.gov

"Highlights of prescribing information - HARLIKU (nitisinone) tablets, for oral use" (PDF). Archived from the original (PDF) on 23 June 2025.

fda.gov

"2023 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Bröijersén A, et al. (1 September 2020). "Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial". The Lancet. Diabetes & Endocrinology. 8 (9): 762–772. doi:10.1016/S2213-8587(20)30228-X. hdl:11365/1115671. PMID 32822600.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Perdomo HD, Guizzo MG, Barletta AB, Nunes RD, Dias FA, Sorgine MH, et al. (22 August 2016). "Tyrosine Detoxification Is an Essential Trait in the Life History of Blood-Feeding Arthropods". Current Biology. 26 (16): 2188–2193. Bibcode:2016CBio...26.2188S. doi:10.1016/j.cub.2016.06.025. PMID 27476595.
Duke SO, Burgess ER, Swale DR, McComic SE (1 August 2023). "Defining the toxicological profile of 4-hydroxyphenylpyruvate dioxygenase-directed herbicides to Aedes aegypti and Amblyomma americanum". Pesticide Biochemistry and Physiology. 194 105532. Bibcode:2023PBioP.19405532M. doi:10.1016/j.pestbp.2023.105532. PMID 37532340.
Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, et al. (July 1995). "Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione". Toxicology and Applied Pharmacology. 133 (1): 12–19. Bibcode:1995ToxAP.133...12E. doi:10.1006/taap.1995.1121. PMID 7597701.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Das AM (2017). "Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)". The Application of Clinical Genetics. 10: 43–48. doi:10.2147/TACG.S113310. ISSN 1178-704X. PMC 5533484. PMID 28769581.
Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Bröijersén A, et al. (1 September 2020). "Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial". The Lancet. Diabetes & Endocrinology. 8 (9): 762–772. doi:10.1016/S2213-8587(20)30228-X. hdl:11365/1115671. PMID 32822600.
Lock EA (2017). "From Weed Killer to Wonder Drug". In Tanguay RM (ed.). Hereditary Tyrosinemia: Pathogenesis, Screening and Management. Advances in Experimental Medicine and Biology. Vol. 959. Cham: Springer International Publishing. pp. 175–185. doi:10.1007/978-3-319-55780-9_16. ISBN 978-3-319-55780-9. PMID 28755195. Retrieved 21 May 2025.
McKiernan PJ (2006). "Nitisinone in the treatment of hereditary tyrosinaemia type 1". Drugs. 66 (6): 743–750. doi:10.2165/00003495-200666060-00002. PMID 16706549. S2CID 24239547.
Perdomo HD, Guizzo MG, Barletta AB, Nunes RD, Dias FA, Sorgine MH, et al. (22 August 2016). "Tyrosine Detoxification Is an Essential Trait in the Life History of Blood-Feeding Arthropods". Current Biology. 26 (16): 2188–2193. Bibcode:2016CBio...26.2188S. doi:10.1016/j.cub.2016.06.025. PMID 27476595.
Haines LR, Casas-Sánchez A, Adung'a VO, Vionette-Amaral RJ, Quek S, Rose C, et al. (26 January 2021). "Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis". PLOS Biology. 19 (1) e3000796. doi:10.1371/journal.pbio.3000796. PMC 7837477. PMID 33497373.
Matias J, Tang X, Cibichakravarthy B, DePonte K, Wu MJ, Fikrig E, et al. (1 January 2024). "Metabolomic changes associated with acquired resistance to Ixodes scapularis". Ticks and Tick-borne Diseases. 15 (1) 102279. doi:10.1016/j.ttbdis.2023.102279. PMID 37972499.
Duke SO, Burgess ER, Swale DR, McComic SE (1 August 2023). "Defining the toxicological profile of 4-hydroxyphenylpyruvate dioxygenase-directed herbicides to Aedes aegypti and Amblyomma americanum". Pesticide Biochemistry and Physiology. 194 105532. Bibcode:2023PBioP.19405532M. doi:10.1016/j.pestbp.2023.105532. PMID 37532340.
Haines LR, Trett A, Rose C, García N, Sterkel M, McGuinness D, et al. (March 2025). "Anopheles mosquito survival and pharmacokinetic modeling show the mosquitocidal activity of nitisinone". Science Translational Medicine. 17 (791) eadr4827. doi:10.1126/scitranslmed.adr4827. PMID 40138457.
Sterkel M, Martins AJ, BP Lima J, L Oliveira P, Vergaray Ramirez MA (2022). "On the use of inhibitors of 4-hydroxyphenylpyruvate dioxygenase as a vector-selective insecticide in the control of mosquitoes". Pest Management Science. 78 (2): 692–702. doi:10.1002/ps.6679. PMID 34647418.
Stavrou-Dowd ZT, Parsons G, Rose C, Brown F, Lees RS, Acosta-Serrano Á, et al. (July 2025). "The β-triketone, nitisinone, kills insecticide-resistant mosquitoes through cuticular uptake". Parasites & Vectors. 18 (1) 316. doi:10.1186/s13071-025-06939-0. PMC 12315382. PMID 40745331.
Rodenburg IL, Harding CO, Hollak CE, Heiner-Fokkema MR, van Spronsen FJ, van Ginkel WG (December 2019). "Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1". Paediatric Drugs. 21 (6): 413–426. doi:10.1007/s40272-019-00364-4. ISSN 1179-2019. PMC 6885500. PMID 31667718.
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, et al. (August 1998). "From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug". Journal of Inherited Metabolic Disease. 21 (5): 498–506. doi:10.1023/A:1005458703363. PMID 9728330. S2CID 6717818.
Kavana M, Moran GR (September 2003). "Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione". Biochemistry. 42 (34): 10238–10245. doi:10.1021/bi034658b. PMID 12939152.
Mitchell G, Bartlett DW, Fraser TE, Hawkes TR, Holt DC, Townson JK, et al. (February 2001). "Mesotrione: a new selective herbicide for use in maize". Pest Management Science. 57 (2): 120–128. doi:10.1002/1526-4998(200102)57:2<120::AID-PS254>3.0.CO;2-E. PMID 11455642.
Moran GR (January 2005). "4-Hydroxyphenylpyruvate dioxygenase". Archives of Biochemistry and Biophysics. 433 (1): 117–128. doi:10.1016/j.abb.2004.08.015. PMID 15581571.
Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, et al. (July 1995). "Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione". Toxicology and Applied Pharmacology. 133 (1): 12–19. Bibcode:1995ToxAP.133...12E. doi:10.1006/taap.1995.1121. PMID 7597701.
Lindstedt S, Odelhög B (1987). "4-Hydroxyphenylpyruvate dioxygenase from human liver". In Kaufman S (ed.). Metabolism of Aromatic Amino Acids and Amines. Methods in Enzymology. Vol. 142. pp. 139–142. doi:10.1016/S0076-6879(87)42021-1. ISBN 978-0-12-182042-8. PMID 3037254.

ncbi.nlm.nih.gov

Das AM (2017). "Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)". The Application of Clinical Genetics. 10: 43–48. doi:10.2147/TACG.S113310. ISSN 1178-704X. PMC 5533484. PMID 28769581.
Haines LR, Casas-Sánchez A, Adung'a VO, Vionette-Amaral RJ, Quek S, Rose C, et al. (26 January 2021). "Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis". PLOS Biology. 19 (1) e3000796. doi:10.1371/journal.pbio.3000796. PMC 7837477. PMID 33497373.
Stavrou-Dowd ZT, Parsons G, Rose C, Brown F, Lees RS, Acosta-Serrano Á, et al. (July 2025). "The β-triketone, nitisinone, kills insecticide-resistant mosquitoes through cuticular uptake". Parasites & Vectors. 18 (1) 316. doi:10.1186/s13071-025-06939-0. PMC 12315382. PMID 40745331.
Rodenburg IL, Harding CO, Hollak CE, Heiner-Fokkema MR, van Spronsen FJ, van Ginkel WG (December 2019). "Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1". Paediatric Drugs. 21 (6): 413–426. doi:10.1007/s40272-019-00364-4. ISSN 1179-2019. PMC 6885500. PMID 31667718.

dailymed.nlm.nih.gov

"Orfadin- nitisinone capsule". DailyMed. 30 November 2021. Retrieved 5 July 2025.
"Orfadin- nitisinone suspension". DailyMed. 20 June 2022. Retrieved 5 July 2025.
"Nityr- nitisinone tablet". DailyMed. 24 May 2024. Retrieved 5 July 2025.

rarediseases.org (Global: 5,181^st place; English: 3,260^th place)

Tanguay RM. "Physician's Guide to Tyrosinemia Type 1" (PDF). National Organization for Rare Disorders. Archived from the original (PDF) on 11 February 2014.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

McKiernan PJ (2006). "Nitisinone in the treatment of hereditary tyrosinaemia type 1". Drugs. 66 (6): 743–750. doi:10.2165/00003495-200666060-00002. PMID 16706549. S2CID 24239547.
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, et al. (August 1998). "From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug". Journal of Inherited Metabolic Disease. 21 (5): 498–506. doi:10.1023/A:1005458703363. PMID 9728330. S2CID 6717818.

sobi.com (Global: low place; English: low place)

"Sobi's Orfadin® oral suspension granted European patent | Sobi". www.sobi.com. 19 January 2016. Retrieved 6 July 2025.

springer.com (Global: 274^th place; English: 309^th place)

link.springer.com

Lock EA (2017). "From Weed Killer to Wonder Drug". In Tanguay RM (ed.). Hereditary Tyrosinemia: Pathogenesis, Screening and Management. Advances in Experimental Medicine and Biology. Vol. 959. Cham: Springer International Publishing. pp. 175–185. doi:10.1007/978-3-319-55780-9_16. ISBN 978-3-319-55780-9. PMID 28755195. Retrieved 21 May 2025.

web.archive.org (Global: 1^st place; English: 1^st place)

"Highlights of prescribing information - HARLIKU (nitisinone) tablets, for oral use" (PDF). Archived from the original (PDF) on 23 June 2025.
"2023 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
Tanguay RM. "Physician's Guide to Tyrosinemia Type 1" (PDF). National Organization for Rare Disorders. Archived from the original (PDF) on 11 February 2014.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Das AM (2017). "Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)". The Application of Clinical Genetics. 10: 43–48. doi:10.2147/TACG.S113310. ISSN 1178-704X. PMC 5533484. PMID 28769581.
Rodenburg IL, Harding CO, Hollak CE, Heiner-Fokkema MR, van Spronsen FJ, van Ginkel WG (December 2019). "Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1". Paediatric Drugs. 21 (6): 413–426. doi:10.1007/s40272-019-00364-4. ISSN 1179-2019. PMC 6885500. PMID 31667718.

Nitisinone (English Wikipedia)

canada.ca (Global: 1,712th place; English: 1,063rd place)

dermnetnz.org (Global: 7,563rd place; English: 5,361st place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

fda.gov (Global: 447th place; English: 338th place)